BGSF: Q1 Earnings Snapshot
PLANO, Texas (AP) — PLANO, Texas (AP) — BGSF, Inc. (BGSF) on Wednesday reported a loss of $722,000 in its first quarter.
The Plano, Texas-based company said it had a loss of 7 cents per share.
The staffing company posted revenue of $63.2 million in the period.
In the final minutes of trading on Wednesday, the company's shares hit $3.20. A year ago, they were trading at $8.96.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
24 minutes ago
- Forbes
Trump Says He'll ‘Probably' Extend TikTok Sale Deadline This Week
President Donald Trump on Tuesday suggested he would 'probably' extend a deadline for ByteDance, TikTok's China-based owners, to divest the social media app before Thursday, marking what would be his third delay after an earlier deal fell through. An order to keep TikTok operational in the U.S. for another 75 days was signed by Trump in April. Trump told reporters on Air Force One he would 'probably' extend a June 19 deadline for ByteDance to divest from TikTok or sell its assets to an American firm, adding, 'Probably have to get China approval, but I think we'll get it.' Another extension would be Trump's third delaying a forced sale or divestment of TikTok, following earlier orders pushing back the deadline on Jan. 20 and April 4, when a deal was reportedly in place for TikTok's operations to be spun off into a new U.S.-based company before Trump's 'Liberation Day' tariffs derailed the talks. Trump told NBC News last month he would 'like to see [a deal] done' for TikTok, adding he had a 'little sweet spot in my heart' for the social media platform and he would be 'willing to give it [the deadline] an extension' if needed. How long Trump would delay TikTok's deadline. Both extensions in January and April stalled a ban on TikTok by 75 days. Several companies have emerged as potential suitors for TikTok's assets, including Amazon, Oracle and Microsoft. Amazon's bid for TikTok would include the entire company, unnamed people familiar with the offer told the New York Times, though some parties involved in the talks 'do not appear to be taking Amazon's bid seriously.' AppLovin reportedly made an offer for TikTok and spoke with billionaire Steve Wynn about backing the deal, after the company told the Trump administration it could address national security concerns about the app if it held ownership. The White House previously spoke with Oracle about a deal that would give the company oversight of TikTok's U.S. data, Politico reported. Trump has also named Microsoft as a possible buyer while saying he hoped there would be a 'bidding war' for TikTok. Legislation requiring TikTok to sell itself to an American company or be banned in the U.S. was signed under President Joe Biden last year. That law followed growing bipartisan national security concerns about the app in recent years, after reports claimed China relied on TikTok's U.S. data to spy on Americans. Forbes previously reported the app spied on journalists, mishandled advertiser data and stored financial data of some creators in China, though ByteDance has denied claims user privacy was compromised. Trump issued an executive order in January shortly after he took office, though the app briefly went dark for U.S. users.
Yahoo
28 minutes ago
- Yahoo
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in HTT mRNA in healthy volunteers The SKY-0515 Phase 1 trial in patients with Huntington's disease reached full enrollment ahead of schedule BOSTON, June 18, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced that the first patient has been dosed in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an investigational oral RNA splicing modulator for the treatment of Huntington's disease (HD). SKY-0515 is designed to reduce the production of both HTT and PMS1 proteins—two key drivers of HD pathology. In a Phase 1 study in healthy volunteers, SKY-0515 demonstrated dose-dependent HTT mRNA reduction, achieving an average of 72% lowering at the highest dose tested. The compound was generally well tolerated across all doses. Additionally, the Company's Phase 1 trial in HD patients, which began in January 2025, completed enrollment ahead of schedule in March 2025. "Dosing the first patient in our FALCON-HD trial marks a significant milestone in our mission to develop a disease-modifying therapy for Huntington's patients," said Bill Haney, Founder and Chief Executive Officer of Skyhawk Therapeutics. "Building on our compelling Phase 1 data, we are eager to assess SKY-0515's potential to make a meaningful difference in the lives of patients affected by this devastating condition." FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial includes multiple sites across Australia and New Zealand. The initial dosing took place at Flinders Medical Centre in Adelaide, Australia. "We are pleased to participate in this important clinical trial and to have dosed the first patient here at Flinders," said Dr. Karyn Boundy, FRACP, Neurologist, Principal Investigator at Flinders Medical Centre. "Given the lack of approved disease-modifying treatments for Huntington's disease, we are hopeful that SKY-0515 could offer a new therapeutic option for patients." "As Skyhawk kicks off their Phase 2/3 FALCON-HD trial in Australia and New Zealand, the international Huntington's community looks forward to expansion worldwide," said Ed Wild, professor of neurology at the University College London. "SKY-0515's unique ability to reduce both HTT and PMS1 could meaningfully enhance therapeutic impact beyond that of lowering HTT alone." About the FALCON-HD TrialFALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial plans to enroll 120 subjects across 10 sites in Australia and New Zealand. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels, or placebo, for a treatment period of at least 12 months. The trial aims to assess the potential of SKY-0515 to modulate RNA splicing and reduce the production of huntingtin (HTT) and PMS1 proteins, which are implicated in the pathology of Huntington's disease. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at and About SKY-0515SKY-0515 is an orally administered small molecule RNA splicing modulator developed through Skyhawk's proprietary platform. It is designed to reduce production of both huntingtin (HTT) and PMS1 proteins, two key contributors to Huntington's disease. SKY-0515 has shown robust, dose-dependent HTT mRNA reduction—up to 72%—in healthy volunteer studies, with favorable safety and tolerability. SKY-0515 is currently being evaluated in a Phase 2/3 clinical trial. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases. Skyhawk's discovery expertise is rooted in its proprietary drug discovery platform, which assesses, identifies, and tests RNA splicing targets and small molecules across a broad range of therapeutic areas and disease states. Skyhawk has built collaborations with multiple pharma partners that leverage Skyhawk's novel platform across disease areas including neurodegenerative disease, autoimmune disease, and oncology. For more information visit Skyhawk ContactsKyle Dow, VP Corporate Logo - View original content: SOURCE Skyhawk Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
30 minutes ago
- CNBC
Gold is near an all-time high—here's how much a Costco bar bought a year ago is worth today
Costco's gold bars are worth a lot more than they were a year ago — and demand is soaring. The bars have been a steady draw since Costco began selling them in 2023, and a sharp rise in spot gold prices seems to have boosted their appeal. In May, the retailer tightened purchase restrictions, limiting members to one transaction, capped at a maximum of two bars, per day. As of Tuesday morning, gold traded around $3,390 per ounce — near a recent record high and roughly 45% higher than it was at this time last year. Historically, investors tend to flock to gold during periods of geopolitical instability, inflation and concern over the strength of the U.S. dollar. Here's how much more a 1-ounce gold bar purchased at Costco in June 2024 could be worth today, based on the listed purchase price and Tuesday's opening spot price. If you bought gold from Costco a year ago, you may be considering selling at a profit. But offloading a gold bar isn't as simple as checking the spot price and pocketing the difference. The spot price offers a benchmark for negotiating prices, but sellers typically receive about 5% to 10% less, depending on where and how they sell, says Jon Ulin, a certified financial planner based in Boca Raton, bullion dealers typically offer in-person evaluations and immediate payment, and may pay 1% to 5% below the spot price for a standard 1-ounce gold bar — often more than pawn shops, The Wall Street Journal reported on April 19, 2024. Online buyers may advertise competitive rates, often with the added convenience of insured shipping. In either case, vetting potential buyers on platforms like Yelp, Google or the Better Business Bureau can help you avoid lowball offers, hidden fees or scams. "I would avoid private buyers or marketplaces like eBay or Facebook Marketplace," says Ulin. "You're dealing with a high-value item and there's a risk of encountering less-than-reputable individuals." Any profits you make from selling gold can be taxed at a higher rate than other investments, such as stocks or bonds. The IRS generally classifies physical gold — such as bars, coins or jewelry — as a collectible for tax purposes, Troy Lewis, a certified public accountant and professor of accounting and tax at Brigham Young University, told CNBC on April 30. The "collectible" classification means that federal long-term capital gains on gold can be taxed at a rate of up to 28%, compared to a maximum of 20% for stocks or real estate. If the gold is sold within one year, any profit is taxed as ordinary income, which could mean an even higher rate, depending on the seller's tax bracket. By selling gold, you might unexpectedly "be adding up the tax bill you pay to Uncle Sam," says Bill Shafransky, a New Canaan, Connecticut-based financial advisor.
